
Opinion|Videos|December 24, 2025
Current Standards of Care in GCA Treatment
Advertisement
Episodes in this series

This video covers the following questions:
- Let’s shift to discuss current treatments. What is the standard of care for GCA?
- While glucocorticoids have been standard of care for patients with GCA, they are known to elevate the risk of cardiovascular, metabolic, and osteoporotic complications. Please share what you have seen in your clinic.
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
One COPD Exacerbation Is Too Many: Vickram Tejwani, MD
4
Monthly PVX108 Raises Peanut Tolerance in Children, With Brian Vickery, MD
5

